CD274 and neutropenia: In the PD-L1 inhibitor plus etoposide group, three patients (2.8%) died (one of neutropenia, one of pneumonia, and one of unknown cause), and five patients (4.3%) in the etoposide group died (two of pneumonia, one of septic shock, and two of respiratory failure).